Great Point Partners
Greenwich, CTfiles as GREAT POINT PARTNERS LLC
$424m in 37 US stocks at the end of 30 June 2026. The top 10 are 53.6% of the money. It changed about 40.5% of the portfolio this quarter.
Value
$424m
Stocks
37
Top 10 share
53.6%
Turnover
40.5%
What changed this quarter
New
Bought for the first time this quarter.
- Abivax SAABVX6.4% of the fund
- Definium TherapeuticsDFTX4.7% of the fund
- Sagimet BiosciencesSGMT3.7% of the fund
- InflaRxIFRX1.6% of the fund
- JATT II AcquisitionJATT1.3% of the fund
- AltimmuneALT1.2% of the fund
- Amanat AcquisitionAMAN1.2% of the fund
- ScynexisSCYX0.9% of the fund
- Enliven TherapeuticsELVN0.8% of the fund
- Rein TherapeuticsRNTX0.6% of the fund
- DBV Technologies S ADBVT0.6% of the fund
Added
Bought more of a stock they already held.
- Vera TherapeuticsVERA6.1% of the fund+201%
- AnnexonANNX4.7% of the fund+40%
- MoonLake ImmunotherapeuticsMLTX3.9% of the fund+71%
- Contineum TherapeuticsCTNM3.6% of the fund+15%
- Immix BiopharmaIMMX3.1% of the fund+265%
- LB PharmaceuticalsLBRX2.4% of the fund+6%
- Opus GeneticsIRD1.9% of the fund+507%
Cut
Sold some of their stake.
- Vor BiopharmaVOR7.4% of the fund-3%
- Climb BioCLYM3.1% of the fund-25%
- Amylyx PharmaceuticalsAMLX3.0% of the fund-60%
- Nektar TherapeuticsNKTR2.9% of the fund-45%
- NeurogeneNGNE2.6% of the fund-30%
- Bright Minds BiosciencesDRUG1.8% of the fund-50%
- Silence TherapeuticsSLN1.2% of the fund-56%
- Palisade BIOPALI1.1% of the fund-33%
- ProMIS NeurosciencesPMN0.3% of the fund-77%
Sold out
Sold their entire stake.
- Apogee TherapeuticsAPGE-100%
- Kalvista Pharmaceuticals-100%
- ImmunovantIMVT-100%
- Jade BiosciencesJBIO-100%
- Zenas BioPharmaZBIO-100%
- Compass TherapeuticsCMPX-100%
- Scynexis-100%
- Context TherapeuticsCNTX-100%
- Unicycive TherapeuticsUNCY-100%
- Tenax TherapeuticsTENX-100%
- PharvarisPHVS-100%
- Avalo TherapeuticsAVTX-100%
- Alkermes plc.ALKS-100%
Holdings
- Abivax SAABVX
- Share
- 6.4%
- Value
- $27m
- Shares
- 204,314
New
- Eupraxia PharmaceuticalsEPRX
- Share
- 1.9%
- Value
- $8m
- Shares
- 1,200,000
Held
- Bright Minds BiosciencesDRUG
- Share
- 1.8%
- Value
- $8m
- Shares
- 109,603
-50%
- JATT II AcquisitionJATT
- Share
- 1.3%
- Value
- $6m
- Shares
- 500,000
New
- Amanat AcquisitionAMAN
- Share
- 1.2%
- Value
- $5m
- Shares
- 500,000
New
- DBV Technologies S ADBVT
- Share
- 0.6%
- Value
- $3m
- Shares
- 156,906
New
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| Vor BiopharmaVOR | 7.4% | $31m | 1,700,000 | -3% |
| Abivax SAABVX | 6.4% | $27m | 204,314 | New |
| Vera TherapeuticsVERA | 6.1% | $26m | 600,836 | +201% |
| Zura BioZURA | 5.9% | $25m | 4,215,930 | Held |
| AlumisALMS | 5.7% | $24m | 856,061 | Held |
| Sol-Gel TechnologiesSLGL | 4.8% | $20m | 274,363 | Held |
| Definium TherapeuticsDFTX | 4.7% | $20m | 425,000 | New |
| AnnexonANNX | 4.7% | $20m | 3,500,000 | +40% |
| Oruka TherapeuticsORKA | 4.1% | $17m | 183,330 | Held |
| MoonLake ImmunotherapeuticsMLTX | 3.9% | $17m | 855,813 | +71% |
| Sagimet BiosciencesSGMT | 3.7% | $16m | 2,029,933 | New |
| Contineum TherapeuticsCTNM | 3.6% | $15m | 921,481 | +15% |
| Immix BiopharmaIMMX | 3.1% | $13m | 1,277,642 | +265% |
| Climb BioCLYM | 3.1% | $13m | 1,000,000 | -25% |
| Amylyx PharmaceuticalsAMLX | 3.0% | $13m | 700,000 | -60% |
| Nektar TherapeuticsNKTR | 2.9% | $12m | 175,000 | -45% |
| NeurogeneNGNE | 2.6% | $11m | 352,180 | -30% |
| LB PharmaceuticalsLBRX | 2.4% | $10m | 317,221 | +6% |
| Opus GeneticsIRD | 1.9% | $8m | 1,970,187 | +507% |
| Eupraxia PharmaceuticalsEPRX | 1.9% | $8m | 1,200,000 | Held |
| Bright Minds BiosciencesDRUG | 1.8% | $8m | 109,603 | -50% |
| InflaRxIFRX | 1.6% | $7m | 3,046,557 | New |
| Relmada TherapeuticsRLMD | 1.4% | $6m | 842,106 | Held |
| JATT II AcquisitionJATT | 1.3% | $6m | 500,000 | New |
| Cullinan TherapeuticsCGEM | 1.3% | $5m | 300,000 | Held |
| AltimmuneALT | 1.2% | $5m | 1,741,232 | New |
| Amanat AcquisitionAMAN | 1.2% | $5m | 500,000 | New |
| RezoluteRZLT | 1.2% | $5m | 951,809 | Held |
| Silence TherapeuticsSLN | 1.2% | $5m | 450,000 | -56% |
| Palisade BIOPALI | 1.1% | $5m | 2,284,819 | -33% |
| EvommuneEVMN | 1.0% | $4m | 325,000 | Held |
| ScynexisSCYX | 0.9% | $4m | 944,292 | New |
| Enliven TherapeuticsELVN | 0.8% | $4m | 70,000 | New |
| HumacyteHUMA | 0.7% | $3m | 3,750,000 | Held |
| Rein TherapeuticsRNTX | 0.6% | $3m | 2,575,000 | New |
| DBV Technologies S ADBVT | 0.6% | $3m | 156,906 | New |
| ProMIS NeurosciencesPMN | 0.3% | $1m | 86,150 | -77% |
Options (5)
- Abivax SAABVX
- Type
- Call
- Value
- $53m
- Contracts
- 400,000
- ImmunityBioIBRX
- Type
- Put
- Value
- $26m
- Contracts
- 3,000,800
- Ultragenyx PharmaceuticalRARE
- Type
- Put
- Value
- $20m
- Contracts
- 600,000
- Galectin TherapeuticsGALT
- Type
- Call
- Value
- $4m
- Contracts
- 800,000
- Anavex Life SciencesAVXL
- Type
- Call
- Value
- $1m
- Contracts
- 521,300
| Company | Type | Value | Contracts |
|---|---|---|---|
| Abivax SAABVX | Call | $53m | 400,000 |
| ImmunityBioIBRX | Put | $26m | 3,000,800 |
| Ultragenyx PharmaceuticalRARE | Put | $20m | 600,000 |
| Galectin TherapeuticsGALT | Call | $4m | 800,000 |
| Anavex Life SciencesAVXL | Call | $1m | 521,300 |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 176.0% since 30 June 2025.
Where the money is
Health care90.4%
Financial services2.5%
Other7.0%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.